What is CING (CING) stock price today?

CING (CING) is currently trading at $4.52, down 2.59% today.

What is CING P/E ratio?

CING's P/E ratio is -1.08. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CING return on equity (ROE)?

CING's return on equity (ROE) is -733.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CING's market cap?

CING has a market capitalization of $25.34M.

NASDAQ · Biotechnology

CING (CING) Stock

$4.52 -2.59% NASDAQ: CING Healthcare

Valuation

Metric	Value
Price	$4.52
Market Cap	$25.34M
P/E Ratio	-1.08
P/B Ratio	8.35
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$11.89
52-Week Low	$3.16
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-733.33%
ROA	-146.67%
ROCE	-1000.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.39
Current Ratio	1.20

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-21.0M	$-18.0M	$-23.0M	$-16.0M	$-20.0M
Net Profit	$-21.0M	$-18.0M	$-24.0M	$-17.0M	$-22.0M
EPS	$-55.80	$-31.20	$-311.99	$-10.20	$-4.13
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$23.0M	$11.0M	$3.0M	$15.0M	$15.0M
Total Liabilities	$2.0M	$8.0M	$10.0M	$7.0M	$13.0M
Cash	$16.0M	$5.0M	$0	$12.0M	$11.0M
Borrowings	$1.0M	$6.0M	$4.0M	$5.0M	$9.0M

Latest News

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® GlobeNewswire · Jul 2, 2026 Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 GlobeNewswire · Jun 16, 2026 Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 TMX Newsfile · Jun 4, 2026 Cingulate Receives Complete Response Letter from FDA for CTx-1301 GlobeNewswire · Jun 2, 2026 CING: Building Its Cash Position Zacks Small Cap Research · May 19, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-10.0M	$-16.0M	$-15.0M	$-18.0M	$-17.0M
Investing Cash Flow	$-2.0M	$0	$0	$0	$0
Financing Cash Flow	$7.0M	$0	$0	$0	$0
Net Cash Flow	$15.0M	$-11.0M	$-5.0M	$12.0M	$-1.0M
Free Cash Flow	$-11.0M	$-16.0M	$-15.0M	$-19.0M	$-17.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-78.91%
Quick Ratio	2.55
Interest Coverage	-20.00
Return 1Y	1.55%
Return 3Y	-97.58%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLR	$1.39	-0.71%	-1.91	$22.12M	0.00%
BCTX	$3.53	+1.73%	-0.04	$6.65M	0.00%
CASICASI Pharmaceuticals, Inc.	$0.15	+3.08%	-0.07	$2.33M	0.00%
CLSDClearside Biomedical, Inc.	$0.41	+0.00%	-0.11	$2.15M	0.00%
ENTOEntero Therapeutics, Inc.	$2.85	-5.00%	-0.82	$13.58M	0.00%

About CING

CING is led by CEO Shane J. Schaffer, employs 13 people, headquartered in US, publicly traded since 2021.

CING stock trades at $4.52 with a market capitalization of $25.34M. The stock is valued at a price-to-earnings (P/E) ratio of -1.08, price-to-book of 8.35, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.16 and $11.89, and currently trades 62.0% below its 52-week high.

On profitability, CING generates a return on equity (ROE) of -733.33%, return on capital employed of -1000.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides